Tag:
Edwards Lifesciences
Latest Headlines
Latest Headlines
Medicare to cover Edwards' Sapien heart valve
For medical device companies, gaining Medicare reimbursement for surgical procedures involving their implants can be a sort of financial holy grail. Edwards Lifesciences ($EW) has reached that point now that the Centers for Medicare & Medicaid Services has agreed to pay for surgery involving its Sapien transcatheter heart valve.
St. Jude, Edwards among those named as potential J&J M&A targets
Analysts think St. Jude Medical ($STJ) and Edwards Lifesciences ($EW) could be eyed by Johnson & Johnson ($JNJ) as potential pickups.
Edwards seeks wider use for Sapien heart valve
Edwards Lifesciences ($EW) wants the FDA to approve its Sapien transcatheter heart valve implant for a broader class of patients.
Medtronic sees positive results with CoreValve
New data presented over the weekend at the European Society of Cardiology Congress 2011 show that Medtronic's ( $MDT ) CoreValve transcatheter aortic valve replacement system maintained its structural
FDA panel votes in favor of Sapien valve
The FDA's Circulatory System Devices Committee gave Edwards Lifesciences ( $EW ) a win Wednesday with a vote recommending the devicemaker's Sapien transcatheter heart valve after an epic session. The
FDA sees promising Edwards valve as safe, effective
An FDA report released Monday showed that Edwards Lifesciences' Sapien heart valve, which can be implanted without major surgery, significantly reduced rates of death versus standard therapy in
FDA panel to review Edwards SAPIEN valve next month
Edwards Lifesciences has announced that an FDA advisory panel is scheduled to review the company's PMA application for its Edwards SAPIEN transcatheter heart valve on July 20. Edwards submitted the
Edwards Lifesciences encouraged by valve system study results
Edwards Lifesciences has reported positive interim data from a European prospective study of its investigational EDWARDS INTUITY valve system. According to the company, surgeons at five centers
Edwards Lifesciences completes $43M Embrella buy
Irvine, CA-based Edwards Lifesciences has completed the acquisition of Embrella Cardiovascular, which has developed an embolic deflector system that can be used during transcatheter heart valve
Edwards Lifesciences ($EW) subpoenaed for heart monitor
The U.S. Attorney's Office for Central California has subpoenaed Edwards Lifesciences ( $EW ) for documents pertaining to its heart monitor recall in 2006. The Vigilance I Monitor was recalled in June
